Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $342.00 price target on Amgen (NASDAQ: AMGN).The analyst commented: "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


